Status:
COMPLETED
Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-73 years
Phase:
PHASE3
Brief Summary
Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the long term safety and effectiveness of vildaglipt...
Eligibility Criteria
Inclusion
- On a stable dose of metformin as defined by the protocol
- Body mass index (BMI) in the range 22-45
- Blood glucose criteria must be met
Exclusion
- Pregnancy or lactation
- Type 1 diabetes
- Evidence of significant diabetic complications
- Evidence of serious cardiovascular complications
- Laboratory value abnormalities as defined by the protocol
- Other protocol-defined exclusion criteria may apply
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 20 2008
Estimated Enrollment :
3118 Patients enrolled
Trial Details
Trial ID
NCT00106340
Start Date
March 1 2005
End Date
May 20 2008
Last Update
December 17 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
East Hanover, New Jersey, United States, 07936
2
Investigative Centers
Nuremberg, Germany